Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioInvent International AB ( (SE:BINV) ) just unveiled an update.
BioInvent International AB announced that it will present updated Phase 1 clinical data for BI-1910, a TNFR2 agonist for treating solid tumors, at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. Despite the successful completion of the single agent dose escalation phase without notable adverse events, BioInvent has decided to pause the development of BI-1910 following a strategic review to focus on advancing other programs, such as BI-1808 and BI-1206. The announcement highlights BioInvent’s strategic shift and its potential implications for stakeholders, as TNFR2 represents a promising target for cancer immunotherapy.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel and first-in-class immuno-modulatory antibodies for cancer therapy. The company has ongoing clinical programs in Phase 1/2 trials for treating hematological cancer and solid tumors. BioInvent’s proprietary F.I.R.S.T technology platform identifies targets and antibodies, generating promising candidates for its clinical development pipeline and providing licensing and partnering opportunities. The company also generates revenue from research collaborations and license agreements with top-tier pharmaceutical companies and produces antibodies for third parties through its fully integrated manufacturing unit.
Average Trading Volume: 82,470
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.78B
Find detailed analytics on BINV stock on TipRanks’ Stock Analysis page.